Ramadhani A Noor1, Ajibola I Abioye1, Ellen Hertzmark2, Anne M Darling2, Said Aboud3, Ferdinand M Mugusi4, Christopher R Sudfeld1,2, Donna Spiegelman1,2,5,6,7, Wafaie W Fawzi1,2,5. 1. Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA. 2. Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA. 3. Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. 4. Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. 5. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA. 6. Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA. 7. Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
Abstract
BACKGROUND: Hematological status may predict HIV disease progression and mortality among adults initiating highly active antiretroviral therapy (HAART). OBJECTIVES: We aimed to examine the relation of anemia and iron status at HAART initiation with survival and morbidity outcomes. METHODS: We conducted a case-cohort study of 570 HIV-infected adults initiating HAART who were enrolled in a trial of multivitamins in Tanzania. Hemoglobin, serum ferritin, and hepcidin concentrations were assessed at HAART initiation and participants were followed up monthly. We adjusted serum ferritin for inflammation using a regression correction method to characterize hematological status. Cox proportional hazards models were used to estimate HRs for mortality and incident clinical outcomes. RESULTS: We found an 83% prevalence of anemia, 15% prevalence of iron deficiency anemia, and 66% prevalence of anemia of chronic diseases (ACD). The prevalence of elevated iron was 33% and 19% had iron deficiency (ID). After multivariate adjustment, severe anemia (HR: 2.57; 95% CI: 1.49, 4.45) and ACD (HR: 4.71; 95% CI: 2.91, 7.62) were associated with increased risk of mortality as compared with nonanemic participants. In addition, both ID (HR: 2.65; 95% CI: 1.08, 7.78) and elevated iron (HR: 2.83; 95% CI: 2.10, 3.82) were associated with increased risk of mortality as compared with normal iron concentrations. Severe anemia and elevated iron concentrations were associated with incident wasting and >10% weight loss (P values <0.05). CONCLUSIONS: Anemia and both ID and elevated iron were associated with increased mortality among HIV-infected adults initiating HAART. Safety and efficacy studies including anemia etiology, timing of HAART initiation, and dose of iron supplementation among HIV patients appear warranted.This trial was registered at clinicaltrials.gov as NCT00383669.
BACKGROUND: Hematological status may predict HIV disease progression and mortality among adults initiating highly active antiretroviral therapy (HAART). OBJECTIVES: We aimed to examine the relation of anemia and iron status at HAART initiation with survival and morbidity outcomes. METHODS: We conducted a case-cohort study of 570 HIV-infected adults initiating HAART who were enrolled in a trial of multivitamins in Tanzania. Hemoglobin, serum ferritin, and hepcidin concentrations were assessed at HAART initiation and participants were followed up monthly. We adjusted serum ferritin for inflammation using a regression correction method to characterize hematological status. Cox proportional hazards models were used to estimate HRs for mortality and incident clinical outcomes. RESULTS: We found an 83% prevalence of anemia, 15% prevalence of iron deficiency anemia, and 66% prevalence of anemia of chronic diseases (ACD). The prevalence of elevated iron was 33% and 19% had iron deficiency (ID). After multivariate adjustment, severe anemia (HR: 2.57; 95% CI: 1.49, 4.45) and ACD (HR: 4.71; 95% CI: 2.91, 7.62) were associated with increased risk of mortality as compared with nonanemic participants. In addition, both ID (HR: 2.65; 95% CI: 1.08, 7.78) and elevated iron (HR: 2.83; 95% CI: 2.10, 3.82) were associated with increased risk of mortality as compared with normal iron concentrations. Severe anemia and elevated iron concentrations were associated with incident wasting and >10% weight loss (P values <0.05). CONCLUSIONS:Anemia and both ID and elevated iron were associated with increased mortality among HIV-infected adults initiating HAART. Safety and efficacy studies including anemia etiology, timing of HAART initiation, and dose of iron supplementation among HIVpatients appear warranted.This trial was registered at clinicaltrials.gov as NCT00383669.
Authors: J Boom; E Kösters; C Duncombe; S Kerr; B Hirschel; K Ruxrungtham; Q de Mast; P Kosalaraksa; S Ulbolyam; T Jupimai; J Ananworanich Journal: HIV Med Date: 2007-09 Impact factor: 3.180
Authors: Joann M McDermid; Assan Jaye; Maarten F Schim van der Loeff; Jim Todd; Chris Bates; Steve Austin; David Jeffries; Akum A Awasana; Akum A Whittlex; Andrew Prentice Journal: J Acquir Immune Defic Syndr Date: 2007-12-01 Impact factor: 3.731
Authors: Abel Makubi; James Okuma; Donna Spiegelman; Claudia Hawkins; Anne Marie Darling; Elizabeth Jackson; Ferdinand Mugusi; Guerino Chalamilla; Wafaie Fawzi Journal: J Int Assoc Provid AIDS Care Date: 2013-06-21
Authors: Paul C Adams; David M Reboussin; James C Barton; Christine E McLaren; John H Eckfeldt; Gordon D McLaren; Fitzroy W Dawkins; Ronald T Acton; Emily L Harris; Victor R Gordeuk; Catherine Leiendecker-Foster; Mark Speechley; Beverly M Snively; Joan L Holup; Elizabeth Thomson; Phyliss Sholinsky Journal: N Engl J Med Date: 2005-04-28 Impact factor: 91.245
Authors: Roland Kupka; Gernard I Msamanga; Ferdinand Mugusi; Paul Petraro; David J Hunter; Wafaie W Fawzi Journal: J Nutr Date: 2007-10 Impact factor: 4.798
Authors: Peter A Minchella; Andrew E Armitage; Bakary Darboe; Momodou W Jallow; Hal Drakesmith; Assan Jaye; Andrew M Prentice; Joann M McDermid Journal: J Nutr Date: 2015-04-22 Impact factor: 4.798